Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 3071013, 6 pages
http://dx.doi.org/10.1155/2016/3071013
Research Article

Proteomic Analysis of Stage-II Breast Cancer from Formalin-Fixed Paraffin-Embedded Tissues

1Department of Botany and Microbiology, Addiriyah Chair for Environmental Studies, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
2Grassland and Forage Division, National Institute of Animal Science, RDA, Seonghwan-eup, Cheonan-si, Chungnam 330801, Republic of Korea
3Department of Medicinal Crop Research, Rural Development Administration, Eumseong, Chungbuk 369-873, Republic of Korea
4Research Department of Plant Biology and Biotechnology, Loyola College, Nungambakkam, Chennai, Tamil Nadu 600034, India
5Proteomics Division, Discovery Research, Dr. Reddy’s Laboratories Ltd., Miyapur, Hyderabad 500049, India
6Sharmila Institute of Medicinal Products Research Academy, Thanjavur 613007, India

Received 30 November 2015; Revised 22 February 2016; Accepted 7 March 2016

Academic Editor: Gagan Deep

Copyright © 2016 Naif Abdullah Al-Dhabi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics,” Cancer Journal of Clinicians, vol. 59, pp. 225–249, 2009. View at Google Scholar
  2. National Cancer Registry Program, “Ten-year consolidated report of the hospital based cancer registries, 1984–1993: an assessment of the burden and care of cancer patients,” Indian Council of Medical Research, New Delhi, India, 2001.
  3. G. Agarwal and P. Ramakant, “Breast cancer care in India: the current scenario and the challenges for the future,” Breast Care, vol. 3, no. 1, pp. 21–27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Agarwal, P. V. Pradeep, V. Aggarwal, C.-H. Yip, and P. S. Y. Cheung, “Spectrum of breast cancer in Asian women,” World Journal of Surgery, vol. 31, no. 5, pp. 1031–1040, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Parkin, “Global cancer statistics in the year 2000,” Lancet Oncology, vol. 2, no. 9, pp. 533–543, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Saxena, C. I. Szabo, S. Chopin et al., “BRCA1 and BRCA2 in Indian breast cancer patients,” Human Mutation, vol. 20, no. 6, pp. 473–474, 2002. View at Google Scholar · View at Scopus
  7. National Cancer Registry Programme, Consolidated Report of The Population Based Cancer Registries 1990–1996, Indian Council of Medical Research, New Delhi, India, 2001.
  8. American Cancer Society, Cancer Facts & Figures 2015, American Cancer Society, Atlanta, Ga, USA, 2015.
  9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” The Lancet, vol. 365, no. 9472, pp. 1687–1717, 2005. View at Publisher · View at Google Scholar
  10. J. Bonneterre, A. Buzdar, J.-M. A. Nabholtz et al., “Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma,” Cancer, vol. 92, no. 9, pp. 2247–2258, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. C. A. Hudis, “Trastuzumab-mechanism of action and use in clinical practice,” New England Journal of Medicine, vol. 357, no. 1, pp. 39–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Baskın, “Changes in concepts of the technological progress: personalized medicine,” Turkish Bulletin of Hygiene and Experimental Biology, vol. 64, pp. 41–48, 2007. View at Google Scholar
  14. J. E. Celis, H. H. Rasmussen, H. Leffers et al., “Human cellular protein patterns and their link to genome DNA sequence data: usefulness of two-dimensional gel electrophoresis and microsequencing,” The FASEB Journal, vol. 5, no. 8, pp. 2200–2208, 1991. View at Google Scholar · View at Scopus
  15. W. H. McDonald and J. R. Yates III, “Shotgun proteomics and biomarker discovery,” Disease Markers, vol. 18, no. 2, pp. 99–105, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. P. S. Gromov, M. Østergaard, I. Gromova, and J. E. Celis, “Human proteomic databases: a powerful resource for functional genomics in health and disease,” Progress in Biophysics and Molecular Biology, vol. 80, no. 1-2, pp. 3–22, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. A. Baak, F. R. C. Path, M. A. J. A. Hermsen, G. Meijer, J. Schmidt, and E. A. M. Janssen, “Genomics and proteomics in cancer,” European Journal of Cancer, vol. 39, no. 9, pp. 1199–1215, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. K. H. Bleicher, H.-J. Böhm, K. Müller, and A. I. Alanine, “Hit and lead generation: beyond high-throughput screening,” Nature Reviews Drug Discovery, vol. 2, no. 5, pp. 369–378, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Burbaum and G. M. Tobal, “Proteomics in drug discovery,” Current Opinion in Chemical Biology, vol. 6, no. 4, pp. 427–433, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. S. Sreenath, K. R. Kumar, G. V. Reddy et al., “Evidence for the association of synaptotagmin with glutathione S-transferases: implications for a novel function in human breast cancer,” Clinical Biochemistry, vol. 38, no. 5, pp. 436–443, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Witzmann and R. A. Grant, “Pharmacoproteomics in drug development,” Pharmacogenomics Journal, vol. 3, no. 2, pp. 69–76, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. D. A. Porter, I. E. Krop, S. Nasser et al., “A SAGE (serial analysis of gene expression) view of breast tumor progression,” Cancer Research, vol. 61, pp. 5697–5702, 2001. View at Google Scholar
  24. Y. M. Coyle, “The effect of environment on breast cancer risk,” Breast Cancer Research and Treatment, vol. 84, no. 3, pp. 273–288, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. L. C. Alldridge and C. E. Bryant, “Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal,” Experimental Cell Research, vol. 290, no. 1, pp. 93–107, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Pongtheerat, M. Treetrisool, and W. Purisa, “Glutathione S-Transferase polymorphisms in breast cancers of Thai patients,” Asian Pacific Journal of Cancer Prevention, vol. 10, no. 1, pp. 127–132, 2009. View at Google Scholar · View at Scopus
  27. X. Wang and Z. H. Huang, “Predictive potential role of glutathione S-transferase polymorphisms in the prognosis of breast cancer,” Genetics and Molecular Research, vol. 14, no. 3, pp. 10236–10241, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Van de Rijn, C. M. Perou, R. Tibshirani et al., “Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome,” American Journal of Pathology, vol. 161, no. 6, pp. 1991–1996, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Jones, A. Mackay, A. Grigoriadis et al., “Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer,” Cancer Research, vol. 64, no. 9, pp. 3037–3045, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Korsching, J. Packeisen, C. Liedtke et al., “The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?” Journal of Pathology, vol. 206, no. 4, pp. 451–457, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Zhang, L. K. Tai, L. L. Wong, L.-L. Chiu, S. K. Sethi, and E. S. C. Koay, “Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer,” Molecular and Cellular Proteomics, vol. 4, no. 11, pp. 1686–1696, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Dowling, P. Meleady, A. Dowd, M. Henry, S. Glynn, and M. Clynes, “Proteomic analysis of isolated membrane fractions from superinvasive cancer cells,” Biochimica et Biophysica Acta, vol. 1774, no. 1, pp. 93–101, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Gao, R. R. Zhao, Y. Xue et al., “Role of enolase-1 in response to hypoxia in breast cancer: exploring the mechanisms of action,” Oncology Reports, vol. 29, no. 4, pp. 1322–1332, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Carracedo, L. C. Cantley, and P. P. Pandolfi, “Cancer metabolism: fatty acid oxidation in the limelight,” Nature Reviews Cancer, vol. 13, no. 4, pp. 227–232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Kim, Y. Lee, and J. S. Koo, “Differential expression of lipid metabolism-related proteins in different breast cancer subtypes,” PLoS ONE, vol. 10, no. 3, Article ID e0119473, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Hatsell, T. Rowlands, M. Hiremath, and P. Cowin, “β-Catenin and Tcfs in mammary development and cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 8, no. 2, pp. 145–158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. F. C. Geyer, M. Lacroix-Triki, K. Savage et al., “β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation,” Modern Pathology, vol. 24, no. 2, pp. 209–231, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. A. S. Syed Khaja, N. Dizeyi, P. K. Kopparapu, L. Anagnostaki, P. Härkönen, and J. L. Persson, “Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer,” PLoS ONE, vol. 8, no. 8, Article ID e72210, 2013. View at Publisher · View at Google Scholar · View at Scopus